Incidence and Risk Factors of Serious Adverse Events during Antituberculous Treatment in Rwanda: A Prospective Cohort Study by Lorent, Natalie et al.
Incidence and Risk Factors of Serious Adverse Events





1, Jef Van den Ende
2, Joannes Clerinx
2
1Internal Medicine Department, Centre Hospitalier Universitaire de Kigali, Kigali, Rwanda, 2Clinical Sciences Department, Institute of Tropical Medicine, Antwerp, Belgium
Abstract
Background: Tuberculosis (TB) and TB-human immunodeficiency virus infection (HIV) coinfection is a major public
health concern in resource-limited settings. Although TB treatment is challenging in HIV-infected patients because of
treatment interactions, immunopathological reactions, and concurrent infections, few prospective studies have
addressed this in sub-Saharan Africa. In this study we aimed to determine incidence, causes of, and risk factors for
serious adverse events among patients on first-line antituberculous treatment, as well as its impact on antituberculous
treatment outcome.
Methods and findings: Prospective observational cohort study of adults treated for TB at the Internal Medicine department
of the Kigali University Hospital from May 2008 through August 2009. Of 263 patients enrolled, 253 were retained for
analysis: median age 35 (Interquartile range, IQR 28–40), 55% male, 66% HIV-positive with a median CD4 count 104 cells/
mm
3 (IQR 44–248 cells/mm
3). Forty percent had pulmonary TB, 43% extrapulmonary TB and 17% a mixed form. Sixty-four
(26%) developed a serious adverse event; 58/167 (35%) HIV-infected vs. 6/86 (7%) HIV-uninfected individuals. Commonest
events were concurrent infection (n=32), drug-induced hepatitis (n=24) and paradoxical reactions/TB-IRIS (n=23). HIV-
infection (adjusted Hazard Ratio, aHR 3.4, 95% Confidence Interval, CI 1.4–8.7) and extrapulmonary TB (aHR 2, 95%CI 1.1–3.7)
were associated with an increased risk of serious adverse events. For TB/HIV co-infected patients, extrapulmonary TB (aHR
2.0, 95%CI 1.1–3.9) and CD4 count ,100 cells/mm3 at TB diagnosis (aHR 1.7, 95%CI 1.0–2.9) were independent predictors.
Adverse events were associated with an almost two-fold higher risk of unsuccessful treatment outcome at 6 months (HR
1.89, 95%CI 1.3–3.0).
Conclusion: Adverse events frequently complicate the course of antituberculous treatment and worsen treatment outcome,
particularly in patients with extrapulmonary TB and advanced immunodeficiency. Concurrent infection accounts for most
events. Our data suggest that deterioration in a patient already receiving antituberculous treatment should prompt an
aggressive search for additional infections.
Citation: Lorent N, Sebatunzi O, Mukeshimana G, Van den Ende J, Clerinx J (2011) Incidence and Risk Factors of Serious Adverse Events during Antituberculous
Treatment in Rwanda: A Prospective Cohort Study. PLoS ONE 6(5): e19566. doi:10.1371/journal.pone.0019566
Editor: Madhukar Pai, McGill University, Canada
Received November 24, 2010; Accepted April 11, 2011; Published May 18, 2011
Copyright:  2011 Lorent et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was funded by Tibotec’s REACH Initiative grant. NL was supported by the Belgian Technical Cooperation in Rwanda. She received a grant
from the Flemisch Research Foundation (FWO), Belgium, in 2010. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: nlorent@itg.be
Introduction
Tuberculosis remains one of the deadliest infectious diseases in
the developing world and the human immunodeficiency virus
(HIV) is its single most important risk factor [1]. Tuberculosis
drug related adverse reactions such as hepatitis, peripheral
neuropathy, gastro-intestinal intolerance and skin rashes com-
monly occur [2]. They can cause significant morbidity and
therefore compromise adherence, eventually contributing to
treatment failure, relapse or emergence of resistant strains [3].
Likewise, tuberculosis treatment interruptions, which are re-
quired if standard tuberculosis treatment is not tolerated, may
result in suboptimal treatment response. Adverse drug reactions
have been associated with older age, female sex, and HIV [2,4,5].
In addition, malnutrition, pre-existent liver disease, genetic
factors, use of concomitant drugs and alcohol are risk factors
more specifically related to liver toxicity [6–9]. Besides drug-
related events, immunological reactions and concurrent infections
can play a role in the clinical deterioration of patients on
antituberculous treatment, particularly in the HIV-infected [10].
In sub-Saharan Africa few prospective studies have dealt with
clinical AEs during antituberculous treatment and their impact
on treatment outcome [11,12].
In this study we aimed to determine incidence, causes of and
risk factors for serious AEs among patients on first-line
antituberculous treatment. We also examined its impact on
antituberculous treatment outcome. Preliminary results have been
previously presented at the Union’s World Conference [13].
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Ethical review
This was an observational cohort study. Patient care followed
standard diagnostic and treatment procedures of the department
of Internal Medicine of the CHUK. Written informed consent was
obtained from all participants involved in the study.The study was
reviewed and approved by both institutional review boards of the
Centre Hospitalier Universitaire de Kigali and the Institute of
Tropical Medicine in Antwerp, as well as by the Rwanda National
Ethics Committee.
Study site and setting
We conducted a prospective cohort study at the Centre
Hospitalier Universitaire de Kigali (CHUK) from May 2008
through January 2010. The CHUK with its 500-bed capacity is
the largest of the four public teaching hospitals in Rwanda.
Patient inclusion and follow-up
We enrolled all adult patients (aged $21 years) - both inpatient
and outpatient – who had started first-line TB treatment for newly
diagnosed TB at the Internal Medicine Department of the
CHUK. We excluded prisoners, patients residing outside greater
Kigali, and patients who were unable or unwilling to provide
written informed consent.
Patients were seen at regularly scheduled visits at 2, 4, 8, 12 and
24 weeks of TB treatment, and were encouraged to return at any
time if new symptoms arose during therapy. Patients who missed a
scheduled visit were contacted by phone or, if this was
unsuccessful, through a TB clinic visit by the study nurse.
Data recorded at intake included demographic information (sex,
age, civil status, educational level, use of tobacco, alcohol, and
traditional medicine) and clinical data (TB presentation, data on
previous TB treatment, HIV serostatus, CD4 within 3 months
before or at TB diagnosis, antiretroviral and cotrimoxazole use,
temperature and body mass index). Full blood count, liver
enzymes, and serum creatinin were determined at baseline, and
follow-up visits. New onset symptoms or signs were documented,
as well as the interval from antituberculous treatment initiation.
When patients’ condition deteriorated, the cause of it was
investigated through additional diagnostic tests such as urine, stool,
cerebrospinal fluid, pleural fluid and ascites analysis, blood culture,
chest radiography, abdominal ultrasound when deemed necessary
by the treating physician. Diagnosis at clinical deterioration and
outcome at 24 weeks were determined for all patients. Since the
study site is a tertiary referral hospital, all patients are referred to
their nearest health centre for directly observed therapy. The study
nurse ascertained the final outcome through contacting the
referring health centres and through consultation of the national
TB register. Outcome of patients that could not be traced was
labelled as unknown.
TB/HIV diagnosis and treatment
Patients were defined as having microbiologically-confirmed
TB if at least one biological specimen was positive for acid-fast
bacilli. Culture for Mycobacterium tuberculosis was done on request
when drug resistance was suspected. Smear-negative or extra-
pulmonary TB was based on standard WHO case definitions
[14]. Initiation of TB treatment in those cases required
assessment by at least two senior physicians from the department,
experienced in TB care.
According to the national protocol, patients with a new
diagnosis of TB receive 6 months of antituberculous treatment
consisting of 2 months of rifampin (R), isoniazid (H), ethambutol
(E) and pyrainamide (Z) followed by 4 months of R and H
(2RHEZ/4RH). In the retreatment regimen streptomycin (S) is
added to the intensive phase: 2SRHEZ/1RHEZ/5RHE.
First-line ART consists of two nucleoside reverse transcriptase
inhibitors (stavudine or zidovudine or tenofovir plus lamivudine)
and a non-nucleoside reverse transcriptase inhibitor (nevirapine
or efavirenz). National guidelines recommend initiation of ART
for all extrapulmonary TB regardless of CD4 count, and
pulmonary TB with CD4 count ,200 cells/mm3 within two to
eight weeks after starting of antituberculous treatment. In case of
pulmonary TB with CD4 counts between 200 and 350 cells/
mm
3 initiation of ART is recommended after the intensive
phase of antituberculous treatment. Preferably, all TB patients
are either switched to or started on an efavirenz-based regimen
because of potential drug interactions of rifampin with
nevirapine.
Definitions
A serious AE was defined as an acute clinical deterioration
occurring after the onset of antituberculous treatment, requiring
any change in treatment and/or hospitalisation. We subdivided
the causes of AEs into: 1) toxic drug reactions, 2) concurrent
infection (or neoplasm), 3) antituberculous treatment failure, 4)
paradoxical reactions or paradoxical TB-associated immune
reconstitution inflammatory syndrome (TB-IRIS).
Data from a preliminary study revealed drug-induced hepatitis
was common while the prevalence of viral hepatitis was very low
(N. Lorent, personal communication). Drug induced liver toxicity
was defined as symptomatic elevation of serum transaminases
(more than three times the upper limit of normal) and/or
jaundice during antituberculous therapy, after exclusion of other
apparent causes. Concurrent infection (proven or suspected) was
defined as an acute febrile illness that occurred after TB diagnosis
and that presented with a sepsis-like syndrome manifested by two
or more of the following conditions: heart rate .90/min,
respiratory rate .20 breaths/min, temperature .38uCo r
,36uC, white cell count .12 000 cells/mm
3 or ,4 000 cells/
mm
3 [15]. We defined paradoxical TB-IRIS according to
consensus clinical case definition for resource-limited settings
[16], adapted to the diagnostic capacities of our setting. A
paradoxical reaction was classified as probable when 1) an initial
favorable response to antituberculous treatment was followed by
2) new onset or recrudescence of TB manifestations and 3) at least
a minimum diagnostic work-up had been done to exclude
potential alternative diagnosis such as poor adherence, drug
reactions, and concurrent infection. A paradoxical reaction was
classified as possible if the abovementioned third condition had
not been fulfilled. Causes of severe AEs could be multiple. They
were determined by consensus of the first and second author
based on the available clinical information. Only the first clinical
event was taken into account.
Unsuccessful treatment outcome includes treatment failure
(excluding three patients with confirmed alternative diagnosis),
default, death, or lost to follow-up at final evaluation.
Statistical analysis
Patients’ demographic and clinical characteristics were de-
scribed in terms of percents, medians and interquartile ranges
(IQR). We calculated frequencies and proportions and used Chi2-
test (or Fisher’s exact) and Student’s t-test (parametrical) or
Wilcoxon rank-sum (non-parametrical data) to compare propor-
tions and medians, respectively. Cut-off values for dichotomous
variables were based on their medians.
Adverse Events on Antituberculous Treatment
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probability of acute clinical deterioration over 24 weeks on TB
treatment. Accounting for the variable time and for multiple
factors potentially affecting their occurrence, we used Cox
proportional hazards multivariate regression to estimate adjusted
hazard ratios (aHR), and their 95% confidence intervals (CI) for
risk factors for serious AEs. The proportional hazard assumption
was tested graphically - by plotting the log (cumulative hazard)
vs follow-up time - and formally using Schoenfeld residuals.
Well-known confounding factors, and factors found to be
associated with the occurrence of an AE with a p-value less
than 0.05 in the univariate model were considered as potential
covariates in the multivariate models. Hepatis B surface antigen
was not included in the modeling given the high number of
missing results (118/253). Patients were censored at the
occurrence of death, loss to follow-up or clinical evaluation on
week 24, whichever occurred first.
To investigate the association between adverse events and death
we used Cox regression with split follow-up time at the occurrence
of a serious adverse event.
Figure 1. Flow diagram of all adult patients who started antituberculous treatment from 1 May 2007–31 July 2009.
doi:10.1371/journal.pone.0019566.g001
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analyses were performed using STATAH software version 10.0
(College Station, Texas, USA).
Results
Between May 2008 and August 2009, 347 patients started first-
line antituberculous treatment for presumptive or confirmed TB.
Acid-fast bacilli smears were positive in 78/145 (54%) patients.
Figure 1 is showing a flow diagram of all assessed TB patients.
Eighty-two patients were not eligible: 54 due to residence outside
the 20 km radius from the hospital, 11 refused to participate, and
9 were less than 21 years of age. Of the 263 enrolled, we excluded
from analysis ten patients who did not return for any follow-up
visit and who could not be traced for the whole study duration.
Baseline characteristics of the remaining 253 patients are shown
in Table 1. TB/HIV co-infected patients were of slightly older age,
were more likely to have smear-negative and/or extrapulmonary
TB, low baseline hemoglobin levels, to have had prior TB, and to
require hospital admission.
One hundred sixty-seven (66%) persons were HIV-seropositive.
Median CD4 count was 104 cells/mm
3 (IQR 44–248 cells/mm
3).
Sixty five (39%) patients were receiving ART at initial TB
diagnosis. Of the 97 patients who qualified for ART at study entry,
55 (33%) were started on ART within a median of 31 (IQR 14–50)
days; of whom 43 (78%) during the intensive phase of
antituberculous treatment. Cotrimoxazole preventive therapy or
dapsone in case of sulfonamide allergy was given to 95% of the
patients.
Sixty-four patients (26%) developed a serious AE, 35% (58/167)
in HIV-infected versus 7% (6/86) in HIV-uninfected individuals.
The commonest were concurrent infection (n=33), drug-induced
hepatitis (n=24) and paradoxical reactions/paradoxical TB-IRIS
(n=20) as shown in Table 2.
In only 9/32 cases a causative organism of concurrent infection
was isolated (Table 2). Drug-induced liver toxicity developed in 22
HIV-infected and two HIV-uninfected individuals, all of whom
were symptomatic (nausea, vomiting, anorexia, abdominal pain
and/or jaundice). Only one case of liver toxicity occurred in an
individual with chronic hepatitis B co-infection. Paradoxical
reactions occurred in 21 HIV-infected individuals (12 probable
and nine possible) and in only one HIV-uninfected person.
Primary multi-drug resistant TB was confirmed in one HIV-
Table 1. Baseline characteristics of 253 tuberculosis patients
by HIV status in a tertiary care hospital in Rwanda.
HIV positive HIV negative p-value
n=167 n=86




36 (30–42) 32 (24–36) 0.0004
Female sex 76 (45.5) 39 (45) ns
Married 77 (46) 32 (37) ns
No formal education 17 (10) 9 (10) ns
Unemployed or student 44 (26) 44 (51) ,0.0001
Alcohol abuse 124 (73) 48 (56) 0.003
Smoking, active 63 (38) 21 (24) 0.033





17,9 (16,0–20,2) 18,9 (16,8–20,4) ns
Hemoglobin (g/dL),
median (IQR)
9,9 (8,4–12) 13,1 (11,6–14,5) ,0.0001
Site of TB
b
Pulmonary 54 (32) 48 (55) 0.001
Extrapulmonary 77 (46) 31 (36)
Pulmonary and
extrapulmonary
36 (22) 7 (8)
Smear positivity (n=144)




6 (7) 1 (2) ns
Previous TB treatment 25 (15) 4 (5) 0.015
Fluconazole treatment
e 32 (19) 0 (0) ,0.0001
Traditional drugs
e 12 (7) 7 (8) ns
Severe adverse event 58 (35) 6 (7) ,0.0001
aBody mass index is defined as the weight in kilograms divided by the square of
the height in meters.
bTB can affect multiples sites in one patient.
cSmear-positivity from any biological specimen, including sputum, lymph node
aspirate, etc.
dHepatitis B surface antigen positive in 6/87 hiv-infected and 1/48 hiv-
uninfected persons.
ewithin one week prior to admission.
p-value,0.05; IQR=interquartile range.
doi:10.1371/journal.pone.0019566.t001
Table 2. Causes of serious clinical events during 6 months
follow-up on antituberculous treatment in 167 HIV-infected







in number of patients (pat) 77 events in 58 pat 6 events in 6 pat





Drug-induced liver toxicity 22 (13%) 2 (2%)
Paradoxical reactions/TB IRIS






Miscellanous 5 (3%) -
Suspected lymphoma 2 -
Suspected Kaposi’s sarcoma 1 -
aillnesses with identified etiologic agent were: Klebsiella pneumoniae bacteremia
(2), Staphylococcus aureus bacteremia (1), Klebsiella pneumoniae urosepsis (2),
cryptococcal meningitis (1), zona ophtalmica (1), Plasmodium falciparum
malaria (1), Escherichia coli dysentery (1).
bin most cases no etiologic agent was identified including ilnesses such as
hepatic abscess, enteritis, cholangitis, bronchopneumonia, urosepsis.
cimmune reconstitution inflammatory syndrome (IRIS) is used according to
consensus case definitions for resource-limited countries [16]; paradoxical
reaction is the term used for HIV-uninfected persons.
doi:10.1371/journal.pone.0019566.t002
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and Kaposi’s sarcoma were suspected in three patients.
The median time to develop an AE was 23 days (IQR 14–51).
As shown in Figure 2, HIV/TB co-infected patients are at a
substantially higher risk to develop an AE within the first two
months of antituberculous treatment.
TB treatment was interrupted in 22/64 (34%) patients who
developed an event, 9% of the total cohort. In 17/22 individuals
this was temporarily and all drugs were successfully reintroduced
within 4 weeks.
As shown in Table 3, HIV-infection (aHR 3.4, 95% CI 1.4–8.7)
and extrapulmonary TB (aHR 2, 95%CI1.1–3.7) were the only
two independent risk factors that remained associated with AEs
after multivariate analysis.
In the 167 TB/HIV co-infected patients, extrapulmonary TB
(aHR 2, 95%CI 1.1–3.9) was the only factor independently
associated with an increased risk of developing a serious AE
(Table 4). No significant associations were found between
developing a serious AE and sex, age, previous TB treatment,
and ART during TB treatment.
Median follow-up time among patients who survived was 175
days (IQR 161–180). Treatment outcomes were ascertained for
225 persons. Of 28 (11.1%) patients who had been transferred out
no information could be found in the hospital’s TB register.
Hundred and sixty (63.2%) patients were successfully treated. Six
(2.4%) defaulted, of whom 4 refused to continue antituberculous
treatment following an event. One confirmed multidrug-resistant
TB patient was classified as treatment failure. Treatment
Figure 2. Kaplan-Meier estimates of serious adverse events by HIV-status for 253 tuberculosis patients. The estimated cumulative
probability to develop an adverse event was significantly higher in HIV/TB co-infected patients: 20.9% (95% CI 15.5–27.9) within the first month of
antituberculous treatment (vs. 3.0% (95% CI 1–10) in HIV-uninfected) and up to 29.9% (95%CI 23.6–37.5) at two months of treatment (vs. 6.9% (95%
CI 3.2–14.9) in HIV-uninfected).
doi:10.1371/journal.pone.0019566.g002
Table 3. Predictors of serious adverse events for all 253 tuberculosis patients in univariate and multivariate analysis.
Variable unadjusted HR 95% CI p-value adjusted HR 95% CI p-value
Age ,35 years 0.97 0.59–1.58 ns -
Female sex 1.25 0.77–2.04 ns -
Hospital admission 3.70 1.93–7.08 ,0.0001 1.76 0.85–3.67 ns
Extrapulmonary tuberculosis 2.74 1.52–4.97 0.001 2.04 1.12–3.72 0.020
Prior tuberculosis history 1.31 0.65–2.64 ns -
Body mass index ,18.5 kg/mm
2 2.01 1.18–3.41 0.010 1.35 0.78–2.34 ns
Hemoglobin ,11 g/dL 2.34 1.40–3.90 0.001 1.17 0.70–1.97 ns
HIV co-infection 5.81 2.51–13.47 ,0.0001 3.42 1.35–8.67 0.009
Smoking 1.06 0.63–1.77 ns -
Alcohol intake 1.02 0.60–1.73 ns -
HR: hazard ratio, Cox proportional hazard regression analysis; 95% CI: 95% confidence interval; p-value,0.05.
doi:10.1371/journal.pone.0019566.t003
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histological confirmation of an alternative diagnosis in 3 patients
(1 non Hodgkin lymphoma, 1 Kaposi’s sarcoma, 1 lung cancer).
AEs were associated with an almost two-fold increased risk of
unsuccessful treatment outcome after 6 months of antituberculous
treatment (HR 1.9, 95%CI 1.3–3.0, p=0.002), as well as death
(HR 9.0, 95% CI 4.7–17.3, p,0.0001). Exploring the impact of
the three commonest causes of serious AEs in this, only (proven or
confirmed) concurrent infection increases more than two-fold the
risk of an unsuccessful outcome (aHR 2.2, 95%CI 1.3–3.7,
p=0.005).
Fifty-five (21.7%) patients died, all but 2/55 were (re)hospital-
ized and 48/55 were HIV infected. In thirty-four patients who did
not experience a serious AE, death occurred at a median of 11
days (IQR 8–18) after a gradual deterioration of the general
condition without development of new clinical signs or symptoms.
Seventeen deaths (6.7%) were attributed to a serious AE and 12/
17 patients presented a sepsis-like syndrome at the time of death.
Discussion
In the present study, serious adverse events frequently
complicated the course of antituberculous treatment, particularly
in HIV-infected individuals. These events occurred despite
successful integration of TB and HIV services, as reflected by
HIV testing and counselling for all TB patients, 95% coverage
with cotrimoxazole preventive therapy, and attempts to initiate
ART in concordance with national guidelines.
Overall, more than a quarter (26%) of the patients developed a
serious clinical event. In a study by Pepper, et al., 40% of the TB
patients experienced clinical deterioration during 24 weeks of
follow-up [12]. However, they used a broader definition of clinical
deterioration. They included both all symptomatic worsening, no
matter which grade of severity, and failure to stabilise within 24
weeks of antituberculous treatment; whereas we mainly focused on
predefined conditions such as concurrent infections, liver toxicity,
paradoxical reactions, and treatment failure, based on the results
of a preliminary study held in our department [17].
HIV-infection was the most important risk factor for developing
a clinical event on antituberculous therapy, as has been extensively
reported by others [12,18–20]. This correlation is due to the
increased risk of drug interactions/toxicity, infections, and TB-
IRIS in HIV-infected individuals.
A substantial part of these AEs resulted from - presumed or
confirmed - concurrent infection, reflecting the profound immune
suppression by HIV (and TB) [12,19],[21]
Often fever in the course of antituberculous treatment is not
thoroughly investigated as it is attributed to the active TB disease
process rather than to a concurrent infection. In low-resource
countries such as Rwanda, diagnosing a concurrent infection in a
TB patient is challenging due to indiscriminate use of antibiotics
and limited diagnostic tools. Furthermore, if no causative
organism is found, distinguishing (presumed) concurrent infection
from drug hypersensitivity or paradoxical reaction/immune
reconstitution syndrome may be problematic [16].
Diagnosis of IRIS remains difficult in sub-Saharan Africa, even
with the prospective use of TB-IRIS case definitions for resource-
limited settings [16]. In previous reports from low-income settings
the proportion of patients developing TB-associated IRIS ranged
from 8–16% [11,22–25]. In the present study, TB-IRIS occurred
in 9% of the patients, despite the rather short time interval
between the initiation of antituberculous drugs and ART and the
low baseline CD4 count, two recognised risk factors [23,26–28].
Consistent with findings from Botswana, drug-induced liver
toxicity occurred in 9% of our patients [29]. However, studies on
hepatotoxicity in TB and HIV co-infected patient populations
from Tanzania, South-Africa and Malawi report much lower
incidence rates ranging from 0.9% to 2% [5,30,31]. We did active
laboratory surveillance for liver disease, potentially overestimating
its occurrence. This is nevertheless unlikely since all hepatic events
were symptomatic. TB-IRIS with hepatic involvement may be
mistaken for hepatotoxicity [32]. Besides HIV infection, we were
unable to identify other potential risk factors of hepatotoxicity such
as traditional medicines, fluconazole [33], ART, and hepatitis B
surface antigen carrier state given the limited number of events.
Drug-induced liver toxicity was reversible when antituberculous
treatment was temporarily withdrawn, and did not result in an
overtly adverse outcome.
Although well below international targets [34], a treatment
success rate of 63% is not surprising for our setting. We attended a
selected patient population of predominantly in-patients, with a
high rate of TB and HIV co-infection and advanced disease which
may be due to late presentation to and late referral from a health
centre, factors well known to worsen TB treatment outcome [35–
38]. The high early mortality rate is consistent with data from
Malawi [36].
Table 4. Predictors of serious adverse events for 167 HIV-infected tuberculosis patients in univariate and multivariate analysis.
Variable unadjusted HR 95% CI p-value adjusted HR 95% CI p-value
Age ,35 years 1.62 0.97–2.71 ns 1.41 0.83–2.40 ns
Female sex 1.30 0.78–2.17 ns -
Smoking 0.91 0.53–1.55 ns -
Alcohol intake 0.78 0.44–1.37 ns -
Hospital admission 2.04 0.97–4.30 ns 1.44 0.65–3.19 ns
Extrapulmonary tuberculosis 2.12 1.12–4.00 0.020 1.99 1.05–3.76 0.036
Prior tuberculosis history 1.05 0.51–2.13 ns -
Body mass index ,18.5 kg/mm2 1.50 0.86–2.61 ns -
Hemoglobin ,11 g/dL 1.40 0.80–2.45 ns -
CD4 count ,100 cells/mm3 1.71 1.01–2.90 0.044 1.55 0.90–2.70 ns
Use of antiretroviral treatment 1.36 0.73–2.52 ns -
HR: hazard ratio, Cox proportional hazard regression analysis; 95% CI: 95% confidence interval; p-value,0.05.
doi:10.1371/journal.pone.0019566.t004
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was associated with a more than two-fold increased risk of
unsuccessful treatment outcome, including death [38]. Delay in
diagnosis and appropriate treatment of sepsis [39], as well as lack
of screening for opportunistic infections in HIV-infected individ-
uals starting ART contribute to poor treatment outcome [40].
Therefore, deterioration in patients receiving antituberculous
treatment should prompt an aggressive search for additional
infections. In low-resource settings with limited diagnostic capacity
this is far from evident.
Although we identified only four patients with bacteraemia, this
may well be underestimated. Sepsis with bacteraemia is common
in Africa and is fuelled by the HIV-pandemic [41]. We were
unable to investigate to which extent disseminated mycobacterial
disease has been the cause of clinical worsening, but in a recent
systematic review on community-acquired bloodstream infections
in Africa Mycobacterium tuberculosis complex accounted for 30% [41].
Limitations of our study basically relate to its design. Studies
within the routine care of a busy single centre tertiary care centre
suffer referral bias. Consequently the extent of the problem of AEs
on antituberculous treatment cannot be precisely determined and
our findings may not be transposed to other settings where HIV-1
associated TB is less common. By including outpatients we
attempted to limit referral bias. Future studies of multicentric
design may better address this issue.
Diagnostic work-up of an AE may have been incomplete
because this was an observational study where the decision to
further investigate was left at the physicians’ discretion, and
because diagnostic tools are lacking. However, these conditions
very well reflect real life situation, even at tertiary care level in
many sub-Saharan African countries.
In summary, AEs frequently complicate the course of
antituberculous treatment and worsen treatment outcome. Con-
current infection accounts for most events. HIV infected patients
with advanced immunodeficiency and extrapulmonary TB are
more likely to develop clinical deterioration. Our data suggest that
deterioration in a patient already receiving antituberculous
treatment should prompt an aggressive search for additional
infections.
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